The human polyomavirus BK (BKV) establishes a latent and asymptomatic infection in the majority of the population. In immunocompromised individuals, the virus frequently (re)activates and may cause severe disease such as interstitial nephritis and haemorrhagic cystitis. Currently, the therapeutic options are limited to reconstitution of the antiviral immune response by tapering of the immunosuppressive medication. T cells are particularly important for controlling this virus, and T cell therapies may therefore provide a highly specific and effective mode of treatment. However, little is known about the phenotype and function of BKV-specific T cells in healthy individuals. donors and show that BKV-specific T cells have a phenotype that is distinct from CMV-and EBV-specific T cells. Lastly, we show that BKV-specific T cells are polyfunctional since they are able to rapidly express IL-2, IFN-γ, tumour necrosis factor α, and to a much lower extent also MIP-1β and CD107a.
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INTRODUCTION
In healthy individuals polyomavirus BK (BKV) establishes a latent or 'smoldering', but asymptomatic infection. However, in immunocompromised individuals, the virus frequently escapes the normal immunological surveillance to become systemically active, after which it may cause severe pathology. BKV elicits interstitial nephritis of the allograft in about 5% of kidney transplant recipients, making it an important cause of graft failure and graft loss. In up to 30% of hematopoietic stem cell transplant (HSCT) recipients, the virus evokes haemorrhagic cystitis, thereby significantly contributing to morbidity and length of hospitalization 1 .
Currently, the main mode of therapy for treating patients suffering from BKV infection comprises reconstitution of the immunological antiviral response. In solid organ transplant recipients this is achieved through tapering of the immunosuppressive medication.
Unfortunately, this comes at the cost of increased allograft rejection, and in HSCT recipients this is an unattractive approach due to a considerable increase in the risk of graft-versushost-disease. So far, antiviral agents, such as cidofovir and leflunomide, have shown little effect on BKV replication in vivo 1 . It is therefore crucial to develop new modes of therapy.
In this regard, the normal T cell response was shown to be very important for keeping BKV at bay 2 
. Treatments that involve the infusion of autologous ex vivo-expanded virus-specific T cells, as well as newer vaccination strategies with autologous antigen presenting cells
pulsed ex vivo with viral antigen, are therefore promising candidates that could provide highly specific and effective modes of therapy 3, 4 . It is well established that different T cell specificities give rise to different T cell phenotypes, which in turn are indeed also related to T cell function 5, 6 . In this regard, little is known about the normal phenotype and function of BKV-specific T cells that are controlling BKV infection in healthy individuals, information that is important to the successful design of effective T cell therapies and vaccination strategies.
In the current study, we used fluorescent tetrameric HLA-A02 complexes presenting four different immunodominant BKV epitopes in order to visualize and characterize circulating BKV-specific CD8 + T cells. Phenotype and functional characteristics of these cells were analysed in 5 healthy HLA-A02-positive adults. Furthermore, these BKV tetramers contain epitopes with a high degree of homology to the corresponding polyomavirus JC (JCV) epitopes, varying from a two amino acid difference to no difference at all. Indeed, crossreactivity between the respective BKV and JCV tetramers was demonstrated [7] [8] [9] [10] . Moreover, antigen-presenting cells pulsed with BKV lysate can activate JCV-specific T cells and vice versa 8 . Therefore, it is highly likely that the BKV-specific CD8 + T cells described in the current study are in fact also JCV-specific CD8 + T cells. Since it is well established that CD8 + T cell specificity correlates with phenotype, we compared the phenotypic characteristics of these 
Isolation of PBMCs
PBMCs were isolated using standard density gradient centrifugation after which they were cryopreserved until the day of analysis.
Tetrameric complexes
All tetrameric complexes were obtained from Sanquin (Amsterdam, Netherlands). For BKV, four different immunodominant epitopes shared by the majority of BKV strains were selected; Two BKV capsid protein VP1 epitopes: BKV VP1-derived AITEVECFL (VP1 p44) and BKV VP1 LLMWEAVTV (VP1 p108) 11 ; and two large T antigen protein (LTAg) epitopes: BKV LTAg LLLIWFRPV (LTAg p579) and BKV LTAg FLHCIVFNV (LTAg p410) 12, 13 .
These were incorporated in phycoerythrin (PE)-labeled HLA-A02 tetrameric complexes. After extracellular staining, antibodies were fixed and the cells were permeabilized 
PBMC peptide cultures

Stimulation assays and cytokine production
Cytokine release after peptide or phorbol 12-myristate 13-acetate (PMA)/ionomycin stimulation was performed as described by Lamoreaux et al. 15 . software, always gating out dead cells and duplets.
Gating strategy
Lymphocytes were gated based the forward scatter and sideward scatter event characteristics. Duplets were then gated out as described above. Live/Dead fixable red cell staining was used to gate out dead or dying cells. CD3 + events were then gated, after which the expression of CD8 was plotted against tetramer-positive events ( Figure   1 and 2). Total CD3 + CD8 + (CD8 + T cells) events were then gated separately from total CD3 + CD8 + tetramer + (virus-specific CD8 + T cells) events. Gates were drawn on total CD8 + T cells, or a major CD8 + T cell population (naive, effector-type or memory), after which they were copied to the virus-specific CD8 + T cells for the following markers: CD45RA
was plotted against CD27 in order to define CD45RA + CD27 + naive-, CD45RA¯ CD27 + memory-and CD45RA +/¯ CD27¯ effector-type cell populations (16); The expression of CCR7 was determined by plotting the former against CD45RA, gates were placed based on the double-positive naive CD8 + T cell population (not shown); CD127 was plotted against KLRG1, gates were placed based on the CD127 + KLRG1 -naive CD8 + T cell population (gates are shown in Figure 4 ); CD49d was plotted against CD45RA, gates were placed based on the CD45RA + CD49d -naive CD8 + T cell population ( Figure 5 ); CD38 was plotted against HLA-DR, gates were placed based on the double-negative CD8 + T cell populations (not shown). Ki-67 was plotted against CD38, gates were placed based on the doublenegative CD8 + T cell population (not shown); granzyme B was plotted against granzyme K, gates were placed based on the double-negative naive CD8 + T cell population ( Figure   7 ); T-bet was plotted against Eomes, gates were placed based on the double-negative naive CD8 + T cell population ( Figure 6 ). Gates for the following markers were placed based on their expression on total alive lymphocytes: CXCR3 was plotted against CD3
within total alive lymphocytes, gates were placed based on the CXCR3 hi CD3 -natural killer cell population ( Figure 5) ; PD-1 was plotted against CD3, gates were placed based on the PD-1 lo CD3 -population (not shown).
STATISTICAL ANALYSIS
The two-tailed Mann-Whitney test was used to analyse differences between T cell populations. A p value less than 0.05 was considered statistically significant.
RESULTS
Circulating BKV VP1-specific CD8 + T cells are detectable after in vitro expansion
In view of the low frequencies in which BKV-specific CD8 + T cells are found in the circulation of healthy individuals, we first cultured CFSE-labelled PBMCs from 25 healthy HLA-A02-positive adults with four different BKV peptides, two derived from the capsid protein VP1, and two from the large T antigen (LTAg) protein, for ten days in the presence of IL-2, in order to determine in which of these donors BKV-specific CD8 + T cells were detectable (7, 11) .
This yielded expanded BKV-specific CD8 + T cell populations that were readily detectable by flowcytometry in fifteen out of twenty-five subjects (60%). Seven of these were found to be positive for the VP1 p44 tetramer (28%), eight for the VP1 p108 tetramer (32%), five for the LTAg p579 tetramer (20%), and none of them for the LTAg p410 tetramer. Four subjects were positive for multiple BKV tetramers (16%) ( Table I) . In contrast to the peptide / IL-2 condition, IL-2-only and peptide-only controls never yielded expanded BKV-specific CD8
T cell populations in this 10-day time window (data not shown). (Figure 1) . Circulating BKV VP1-specific CD8 + T cells are resting memory cells
We then measured the expression of a wide variety of T cell markers in order to determine the phenotype of the BKV-specific CD8 + T cells. For comparison, the expression of the same markers was determined on HLA-A02-epitope restricted CMV-, EBV-and Flu-specific CD8 + T cells circulating in the same five subjects (Table II and Figure 2 ). Figure 3A , we found that BKV VP1-specific T cells were CD45RA¯, denoting them as antigen-experienced cells. Moreover, the majority of them expressed CD27 but lacked CCR7, marking them as being predominantly memory, and more specifically as 'effector-memory' T cells (T EM ) ( Figure 3C ) 16, 17 .
As shown in
The memory phenotype was supported by a high expression of CD127, the IL7-receptor by the different virus-specific T cells did not differ significantly from each other ( Figure 4C ).
In contrast, the expression of CD127 by CMV-and EBV-specific T cells was significantly lower when compared to BKV-and Flu-specific T cells ( Figure 4B ).
With regard to their activation status, BKV-specific T cells did not express the activation markers CD38 or HLA-DR, or the marker of active proliferation, Ki-67 (data not shown).
PD-1, a marker of T cell exhaustion or activation, was expressed by nearly 20% of BKVspecific T cells but did not differ significantly from total CD8 + T cells, CD8 + memory T cells or the other virus-specific T cells (data not shown).
In conclusion, circulating BKV VP1-specific CD8 + T cells in healthy adults have a memory phenotype and can be considered to be in a 'resting' state since they did not express activation markers and were not actively proliferating.
Circulating BKV VP1-specific CD8 + T cells highly express the homing markers CD49d and CXCR3
BKV is generally accepted to latently reside in epithelial cells lining the urogenital tract.
However, in immunocompetent individuals, the virus has also been detected in the central nervous system, the intestines and in saliva [19] [20] [21] . Since BKV-specific T cells are present in the circulation, one could theorize that they are trafficking to a site of viral (re)activation.
Thus, we determined the expression of several specific T cell homing markers, in order to elucidate to which sites BKV-specific CD8 + T cells can migrate.
BKV-specific cells lacked expression of CD103, the alpha E integrin chain, a marker for tissue-resident T cells that is also expressed by a small proportion of circulating regulatory CD8 + T cells si 22 . The cells did highly express CD49d ( Figure 5B) , the integrin α4 chain that mediates T cell migration through endothelial-and epithelial barriers into various tissues and also through the blood-brain barrier [23] [24] [25] . However, since CD49d was also highly A. Dot plots displaying the expression of KLRG1 and CD127 by BKV VP1 p108 (subject 4), BKV VP1 p44 (subject 9), CMV, EBV (subject 6), and Flu (subject 4) tetramer + cells in black presented as an overlay on total CD8 + T cells in grey. Anti-KLRG1 fluorescence intensity is plotted on the y axis and anti-CD127 fluorescence intensity on the x axis. Percentages of tetramer + T cells are shown. B. Percentages of CD8 + T cells, CD8 + CD45RA¯CD27 + memory T cells, and BKV VP1 (n = 5), CMV PP65 (n = 3), EBV BMLF1 (n = 3), and Flu MP1 (n = 3) specific CD8 + T cells expressing CD127 (n = 5 subjects; median, IQR). Asterisks mark statistically significant differences between BKV VP1-specific T cells and the respective T cell population, as defined by a P value of <0.05. C. Percentages of CD8 + T cells, CD8 + CD45RA¯CD27 + memory T cells, and BKV VP1 (n = 5), CMV PP65 (n = 3), EBV BMLF1 (n = 3), and Flu MP1 (n = 3) specific CD8 + T cells expressing KLRG1 (median, IQR). expressed on T cells specific for other viruses, this appeared not to be a specific treat of BKV-specific T cells (Figure 5B/D) . BKV-specific T cells expressed high levels of CXCR3, a chemokine receptor which has been shown to mediate T cell homing to reactive lymph nodes, stressed epithelium and sites of inflammation in a general sense 26, 27 . Interestingly, Functionality of circulating BKV VP1-specific CD8 + T cells
Next, we wanted to determine whether the BKV VP1-specific CD8 + T cells are capable of producing cytokines immediately upon stimulation. Therefore, we stimulated the cells with PMA/ionomycin to subsequently measure the intracellular presence of IL-2, IFN-γ, TNF-α, MIP-1β and CD107a. Due to stimulation-induced T cell receptor (TCR) internalization there is an inverse correlation between the degree of stimulation and the ability to detect virusspecific T cells with tetramers. As a consequence, we could detect BKV-specific T cells only in the PBMC fractions of subject 4 and 9 after PMA/ionomycin stimulation. In the other three subjects, the already few tetramer-positive events had become undetectable after stimulation (data not shown). Upon PMA/Ionomycin stimulation, BKV VP1-specific CD8 + T cells from both subjects displayed a polyfunctional profile: nearly 11% of BKV VP1 p108-specific CD8 + T cells in subject 4 were able to rapidly express all five proteins (IL-2, IFN-γ, TNF-α and to a lesser extent also MIP-1-β and CD107a) upon stimulation.
About 23% excreted a combination of four, and 52% excreted a combination of three of these ( Figure 8A/B) . In subject 9, about 4% of VP1p44-specific CD8 + T cells excreted all five proteins, 26% excreted a combination of four, and about 56% produced a combination of three of these proteins. In both subjects the T cells most often produced the combination of IL-2, IFN-γ and TNF-α ( Figure 8B ). + T cells expressing T-bet. Due to insufficient BKV tetramer-positive events after intracellular staining, BKV tetramer data from subject 6 were excluded from this analysis (median, IQR). CMV pp65-specific T cells showed a trend toward a higher expression of T-bet than BKV-specific T cells, P = 0.057. C. Percentages of CD8 + T cells, CD8 + CD45RA¯CD27 + memory T cells, and BKV VP1 (n = 4), CMV PP65 (n = 3), EBV BMLF1 (n = 3), and Flu MP1 (n = 3) specific CD8 + T cells expressing Eomes. Due to insufficient BKV tetramer-positive events after intracellular staining, BKV tetramer data from subject 6 were excluded from this analysis (median, IQR). CMV pp65-and EBV BMLF-1-specific T cells showed a trend toward a higher expression of Eomes than did BKV-specific T cells; for both, P = 0.057.
We then repeated the experiment with cognate peptide stimulation. In order to determine the optimal peptide concentration at which tetramer-positive events were detectable while the cells were also still responding in the sense of cytokine production, we tested peptide concentrations ranging from 1000 ng/ml to 0.05 ng/ml (data not shown). In subject 4, BKV-specific T cells were detectable and functionally active at 1 ng/ml. The higher concentrations (1000, 100 and 10 ng/ml) rendered the detection of + T cells expressing granzyme B. Due to insufficient BKV tetramerpositive events after intracellular staining, BKV tetramer data from subject 6 were excluded from this analysis (median, IQR). Asterisks mark statistically significant differences between BKV VP1-specific T cells and the respective T cell population, as defined by a P value of <0.05. C. Percentages of CD8 + T cells, CD8 + CD45RA¯ CD27 + memory T cells, and BKV VP1 (n = 4), CMV PP65 (n = 3), EBV BMLF1 (n = 3), and Flu MP1 (n = 3) specific CD8 + T cells expressing granzyme K. Due to insufficient BKV tetramerpositive events after intracellular staining, BKV tetramer data from subject 6 were excluded from this analysis (median, IQR). CD8 + memory T cells showed a trend toward higher expression of granzyme K than did BKV-specific T cells, P = 0.06.
BKV-specific T cells impossible, again due to TCR internalization and their subsequent inability to bind the tetramer. In subject 9, BKV-specific T cells were only detectable and functionally active at 1000 ng/ml. In both subjects, the stimulus provided by the lower concentrations proved to be insufficient to trigger cytokine production (data not shown). In contrast to the tetramer-negative CD8 + T cells, a considerable percentage of BKV-specific T cells in both subjects also produced the same proteins in response to their cognate peptide ( Figure 8A) . The extremely low frequencies of BKV-specific CD8 + T cells in the circulation fit the finding that BKV is normally not detectable in this compartment and is residing at distal sites of viral latency, such as the kidney 33 . Indeed, in a minority of healthy persons BKV is episodically shed in the urine 33, 34 . Unfortunately, due to their even lower frequencies in the circulation, we were unable to perform an ex vivo characterization of BKV LTAg-specific CD8 + T cells. LTAg is a non-structural protein that is expressed only during the early phase of viral replication, and during non-permissive infection 1 . The dominance of VP1-specific T cells over LTAg-specific T cells is in line with lower LTAg-specific antibody serum titres when compared with VP1-specific antibody titres 35, 36 . The discrepancy between VP1 and LTAg expression during the viral replication cycle, and as such, the variations in antigen exposure, could explain the differences in population size of VP1-specific-and LTAgspecific T cells.
The function of BKV VP1-specific CD8 + T cells in the circulation might be dual;
preventing BKV from entering the circulation, which is a common occurrence in severely immunocompromised individuals, and/or patrolling the circulation for local or distal BKV activity 1 . Indeed, BKV-specific cells expressed high levels of CXCR3, known to mediate T cell homing to reactive lymph nodes, stressed epithelium and sites of inflammation [25] [26] [27] .
Also, a small proportion expressed the central memory marker CCR7, which allows cells to migrate to lymphoid tissue. Furthermore, owing to their high expression of CD49d these cells have the capacity to migrate through the blood-brain-barrier, pointing to the central nervous system as a latent niche of BKV infection, as was proposed previously 20 . Considering that BKV-specific T cells also recognize epitopes of the JCV, high CD49d expression might be a likely explanation for the association between treatment with the anti-CD49d monoclonal natalizumab and the emergence of progressive multifocal leukoencephalopathy, a severe JCV-mediated neurological disorder 37, 38 . However, the similarly high expression of CD49d by all the other circulating virus-specific CD8 + T cells perhaps rather emphasizes the neurotropism of the polyomaviruses, as well as the importance for BKV-, or 'polyomavirus-specific' T cells, to be present in the central nervous system 24 .
It has been demonstrated quite extensively that different pathogens can drive the differentiation of selective CD8 + T cell subsets 5, 6, 39, 40 . Indeed, we show here that BKVspecific CD8 + T cells have a phenotype that is distinct from CMV-and EBV-specific T cells circulating in these same donors, while sharing some phenotypic aspects with Flu-specific T cells, such as the high expression of CD127, CXCR3 and the low expression of Eomes.
The latter struck us as particularly interesting since both BKV-and Flu-specific CD8 + T cells mainly comprise CD127 + memory cells and Eomes was proposed to be important for the generation of CD8 + memory T cells 41 . Also, it is remarkable that memory T cells, specific for viruses with two entirely different modes of infection, resemble each other in so many aspects, adding to the model of T cell differentiation as previously proposed by Appay et al. 5 . Perhaps such phenotypic similarities could be explained by both T cell populations having been abstained from specific extracellular signals for an extended period of time, knowing that BKV is normally not found in the circulation while Flu is thought to be cleared from the body after infection. Previously, we showed that circulating virus-specific T cells differ significantly from their counterparts residing in lymph nodes or the lungs, demonstrating how the tropism of the virus is also an important determinant of the T cell phenotype 23, 42 . Local BKV-specific CD8 + T cells, could very well display more of an effector phenotype, perhaps readily expressing granzyme B, in order to confer a more specialized defence at sites where the immunogenic pressure is higher. Indeed, if these circulating T EM cells are recruited to a site of BKV reactivation, they may generate or reinforce the local T cell-mediated defence. Therefore, it is crucial to also assess the characteristics of tissue-resident BKV-specific T cells, for example those residing in the urogenital tract and/or the central nervous system. Lastly, considering crucial role of CD4 + helper T cells in clearing viral infection, as well as the existence of cytotoxic CD4 + T cells, knowledge about the BKV-specific CD4 + T cell phenotype and function should be a primary research focus in this field 43 . Unfortunately, this is currently hindered by specific technical limitations, amongst which importantly the lack of available MHC class II tetramers.
In conclusion, these data shed light on the phenotype and function of circulating BKVspecific CD8 + T cells in healthy adults. This information allows for a future comparison with BKV-specific CD8 + T cells circulating in immunocompromised individuals, and their tissue-resident counterparts. These data may prove to be helpful for the design of new immunotherapeutic options for the treatment of BKV-associated disease.
